Latest Commercialisation News

Mesoblast has raised A$260 million through a global private placement to fund the US commercial launch of its FDA-approved cell therapy Ryoncil® and accelerate clinical development in chronic low back pain.

Calix Limited has extended its Share Purchase Plan closing date to January 31, 2025, offering eligible shareholders more time to invest up to $30,000 each. The company may close the plan early if subscriptions exceed $5 million, signaling strong investor interest in its decarbonisation technology.

Livium and Mineral Resources have agreed to extend their joint development agreement, funding additional optimisation activities for the LieNA® lithium extraction technology and setting the stage for a 50/50 joint venture.

Invictus Energy has successfully renewed its SG 4571 licence in Zimbabwe’s Cabora Bassa Basin for an additional three years, enabling continued exploration and development at the Mukuyu gas discovery.

4DMedical has landed a paid pilot contract with the US Department of Defense to deploy its CT:VQ™ lung imaging technology on active-duty personnel, marking a significant step before FDA submission and spotlighting a billion-dollar market opportunity.

EBR Systems has announced a rescheduling of the FDA Pre-Approval Inspection for its wireless cardiac pacing device to January 14, 2025, while maintaining its regulatory approval timeline for Q1 2025 and a commercial launch later in the year.